Skip to main content
MyPeptideMatch

Retatrutide vs Tirzepatide: Which Is Right for You?

Quick verdict

Tirzepatide is the practical choice today: it is a dual GIP/GLP-1 agonist that is FDA-approved (Mounjaro for type 2 diabetes, Zepbound for obesity) and available by prescription now. Retatrutide is a triple GLP-1/GIP/glucagon agonist that produced higher weight loss in its Phase 3 TRIUMPH-1 trial (~28.3% at 80 weeks vs tirzepatide's ~22.5% at 72 weeks), but it is still investigational — Eli Lilly plans to submit it to the FDA in early 2027, and there is no head-to-head or completed cardiovascular-outcomes data. If you need treatment now, tirzepatide is the approved option; retatrutide is the compound to watch as it heads to the FDA.

Side-by-Side Comparison

AttributeRetatrutideTirzepatide
ClassTriple Incretin AgonistGIP/GLP-1 Receptor Agonist
FDA StatusResearch UseFDA Approved
Primary UsesWeight Loss, Type 2 Diabetes, Metabolic HealthWeight Loss, Type 2 Diabetes
AdministrationSubcutaneous injectionSubcutaneous Injection
Typical DosingInvestigational — no FDA-approved dose. Phase 2 obesity trials used 2, 4, 8, and 12 mg once-weekly subcutaneous injections, titrated gradually over roughly 24 weeks, with 12 mg producing the greatest weight loss. These figures are trial reference data, not a prescribable regimen.—
Evidence Level——
Common Side EffectsNausea, Vomiting, Diarrhea, Constipation, Decreased appetite, Elevated resting heart rate—

Retatrutide vs Tirzepatide: How the Triple Agonist Compares to the Dual Agonist

Key Takeaways

  • Mechanism: Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide adds a third target, the glucagon receptor, making it a triple agonist.[1][2]
  • Weight loss: Retatrutide reached ~28.3% mean weight loss at 12 mg over 80 weeks (Phase 3, TRIUMPH-1), while tirzepatide reached ~22.5% at 15 mg over 72 weeks (Phase 3, SURMOUNT-1) — impressive for both, but not a head-to-head comparison.[3][4]
  • FDA status: Tirzepatide is approved and available now (Mounjaro, Zepbound). Retatrutide is investigational; Eli Lilly plans to submit it to the FDA in the first quarter of 2027.[5]
  • Evidence maturity: Both now have Phase 3 efficacy data. Tirzepatide adds years of real-world use; retatrutide's Phase 3 results so far are topline releases, and its dedicated cardiovascular-outcomes trial is still running.[4][5]
  • Bottom line: For treatment today, tirzepatide is the approved option. Retatrutide posted the bigger Phase 3 numbers and could be approved as early as late 2027.

What Are Retatrutide and Tirzepatide?

Tirzepatide is a 39-amino-acid peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is FDA-approved and marketed by Eli Lilly as Mounjaro for type 2 diabetes (2022) and Zepbound for chronic weight management (2023), dosed once weekly by subcutaneous injection.[3]

Retatrutide (Eli Lilly, compound designation LY3437943) is the first molecule to activate three metabolic receptors at once — GLP-1, GIP, and glucagon. It is still investigational: three Phase 3 trials reported positive results in 2026, and Lilly plans to submit it to the FDA in early 2027.[4][5]

Mechanism of Action Differences

The core difference is one extra receptor. Both drugs use GLP-1 activation to slow gastric emptying and reduce appetite, and GIP activation to amplify glucose-dependent insulin release. Retatrutide layers glucagon receptor agonism on top of that. In the context of GLP-1 co-activation, glucagon receptor agonism increases energy expenditure (resting calorie burn) and drives fatty-acid oxidation in the liver, rather than raising blood sugar the way glucagon does on its own.[1] That added "energy-output" lever is the pharmacological explanation for retatrutide's higher trial weight-loss figures.

Receptors targetedGLP-1 + GIP + glucagonGLP-1 + GIP
Drug classTriple incretin agonistDual incretin agonist
Added lever vs the otherGlucagon (energy expenditure, liver fat)—
AdministrationSubcutaneous, once weeklySubcutaneous, once weekly
DeveloperEli Lilly (LY3437943)Eli Lilly (Mounjaro / Zepbound)

Effectiveness Comparison

Both drugs post the highest weight-loss numbers in their respective classes, but they come from different trials at different durations, so any direct percentage comparison is indirect.

In the Phase 3 TRIUMPH-1 trial, retatrutide at 12 mg produced a mean weight loss of ~28.3% (70.3 lbs) at 80 weeks versus 2.2% on placebo, with 45.3% of participants losing at least 30% of body weight.[4] Its earlier Phase 2 trial, published in the New England Journal of Medicine, showed ~24.2% at 48 weeks.[2] In the Phase 3 SURMOUNT-1 trial, tirzepatide at 15 mg produced ~22.5% mean weight loss at 72 weeks, with about 57% of participants losing at least 20%.[3]

Peak mean weight loss~28.3% (12 mg, 80 wk)~22.5% (15 mg, 72 wk)
Trial phasePhase 3 (TRIUMPH-1)Phase 3 (SURMOUNT-1)
Highest dose studied12 mg weekly15 mg weekly
Cardiovascular-outcomes dataOutcomes trial ongoingSURPASS-CVOT
FDA statusInvestigational (FDA submission planned Q1 2027)Approved

The honest read: retatrutide's ceiling looks higher, and that now holds in Phase 3, not just Phase 2. But the trials differ in length and population, and TRIUMPH-1 enrolled people with a higher average starting BMI (40). Cross-trial comparisons cannot establish that retatrutide is definitively "better."

Side Effect Profiles

Both drugs share the gastrointestinal side-effect pattern common to the GLP-1 class — nausea, vomiting, diarrhea, and constipation — concentrated during the dose-escalation phase and generally dose-dependent.[2][3]

  • Tirzepatide: GI effects are the dominant adverse events across the SURMOUNT and SURPASS programs and typically ease at a stable maintenance dose. It carries a class label warning regarding thyroid C-cell tumors (based on rodent data) and the usual class-level pancreatitis and gallbladder considerations.[3]
  • Retatrutide: The same GI pattern appears in Phase 2 and Phase 3 — at 12 mg in TRIUMPH-1, 42.4% reported nausea vs 14.8% on placebo — plus dysesthesia (skin tingling or sensitivity) in 12.5% vs 0.9%.[4] The glucagon-receptor component has been associated with modest increases in resting heart rate in trials — a signal that warrants cardiovascular monitoring and that does not have a direct counterpart in tirzepatide's profile.[1][2]

The critical asymmetry is data maturity: tirzepatide has years of post-marketing surveillance across millions of patients, while retatrutide's safety picture rests on trials of up to two years.

This is where the two diverge most sharply.

  • Tirzepatide is approved and prescribable now. It is not a controlled substance and is covered by many insurance plans for its approved indications, with cash-pay and savings-program options otherwise.[3]
  • Retatrutide isn't FDA approved yet, so there's no prescription or compounding pathway. Legal access is through a clinical trial or, since August 2026, Lilly's narrow early-access program for adults with refractory obesity who can't join a trial.[6]

Products sold online as "retatrutide" aren't Lilly's drug and aren't regulated, so their purity and dose can't be verified. See our guide on where retatrutide stands and how it compares for the current status.

Which Is Right for You?

If you are choosing a treatment you can actually start, the comparison is straightforward: tirzepatide is the option that exists, is approved, and has mature safety and efficacy data. It is a reasonable first-line incretin therapy for obesity or type 2 diabetes when prescribed and monitored by a clinician.

Retatrutide is the more powerful mechanism on paper and the most closely watched compound in the obesity pipeline, but it is not a prescription you can fill today — it is investigational, and its long-term safety and cardiovascular effects are still being studied. If the triple-agonist mechanism interests you, a clinical trial or Lilly's early-access program is the current path, and any decision belongs in a conversation with your provider.

For deeper dives, see the full retatrutide profile, the tirzepatide profile, and — if you're comparing the approved options — semaglutide vs tirzepatide.

References

  1. Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." Lancet. 2023;402(10401):529-544. PMID: 37385280
  2. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526. PMID: 37366315
  3. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." SURMOUNT-1 Trial. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
  4. Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." News release. May 21, 2026.
  5. Eli Lilly and Company. "Lilly's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C." News release. July 23, 2026.
  6. Grossi G. "Lilly Expands Retatrutide Access Amid Doctor Pushback." AJMC. August 5, 2026.

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.

Looking to buy Retatrutide and Tirzepatide for research?

Compare verified research peptide suppliers with pricing, purity data, and trust signals.

Learn more about RetatrutideLearn more about Tirzepatide

Find a Clinic

Find a clinic that offers Retatrutide or Tirzepatide near you.

Browse Peptide Therapy Clinics

MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.